Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Cynata to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York

Posted on: 05 Sep 17

MELBOURNE, Australia, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), announced today it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference. The conference is being held on September 10-12, 2017 in New York City.

The Rodman & Renshaw conference is sponsored by H. C. Wainwright & Co., a leading Wall Street investment bank, with a strong reputation in life sciences. Over 2,000 institutional and other investors are expected to attend the conference, each with a significant interest in the life sciences sector.

Dr Ross Macdonald, Managing Director and CEO, will provide an overview of the Company and its unique Cymerus™ platform during the live presentation and will also be participating in one-on-one meetings with U.S. and international investors and potential partners who are registered to attend the conference. A copy of the presentation will be made available on Cynata’s website.

If you are an institutional investor, and would like to attend the Company’s presentation, please visit the Rodman & Renshaw website to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Event: 19th Annual Rodman & Renshaw Global Investment Conference
Date: September 11, 2017
Time: 3:00pm (US Eastern Time)
Location: Holmes II Room; Lotte New York Palace Hotel in New York City

About Cynata Therapeutics (ASX:CYP)
Cynata Therapeutics Limited (ASX:CYP) is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus™ stem cell technology platform. Cymerus overcomes critical issues in the production of therapeutic mesenchymal stem cells (MSCs) by enabling the economical manufacture of commercial-scale MSCs, independent of multi-donor limitations. Cymerus’ novel approach utilises induced pluripotent stem cells (iPSCs) derived from a single blood donation to generate mesenchymoangioblasts (MCAs), a precursor that is used to manufacture an unlimited number of therapeutic MSCs. Cynata’s unique “off-the-shelf” Cymerus platform has the potential to create a new standard in the development and manufacture of stem cell therapeutics.

CONTACT: CONTACTS: Dr Ross Macdonald, CEO, 0412 119343, Daniel Paproth, Australia Media Contact, 0421 858 982,   Laura Bagby, U.S. Media Contact, 312-448-8098, lbagby@6degreespr.comGlobeNewswire

Last updated on: 05/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.